BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:QLS1304 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of QLS1304\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06823609-9171@assetmemo.bio
DTSTAMP:20261121T005427Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:QLS1304: Phase 1 readout est. (NCT06823609)
DESCRIPTION:QLS1304\, phase 1.\nStudy: Phase I Clinical Study of QLS-1304 i
 n the Treatment of Patients With Advanced Malignant Tumors\nEstimated prim
 ary completion: November 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/qls1304#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06823609
URL:https://assetmemo.bio/drug/qls1304#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07235176-9171@assetmemo.bio
DTSTAMP:20261121T005427Z
DTSTART;VALUE=DATE:20281102
DTEND;VALUE=DATE:20281103
SUMMARY:QLS1304: Phase 1/2 readout est. (NCT07235176)
DESCRIPTION:QLS1304\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy i
 n the Treatment of ER+/HER2- Breast Cancer Patients\nEstimated primary com
 pletion: 2 November 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/qls1304#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07235176
URL:https://assetmemo.bio/drug/qls1304#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
